ㆍDAILY PROGRAMㆍPROGRAM AT A GLANCE

DAILY PROGRAM

08:30-09:30

Symposium 2-1. Circulating Hepatitis B Virus Markers: What Are Their Roles?

  • 09:30-08:45

  • Role of Ultra-High Sensitivity HBsAg Assay in Managing Chronic Hepatitis B

  • 08:45-09:00

  • Role of HBcrAg in Managing Chronic Hepatitis B

  • 09:00-09:15

  • Role of HBV RNA in Managing Chronic Hepatitis B

  • 09:15-09:30

  • Role of Hepatitis B Virus Immunological Serum Markers in Managing Chronic Hepatitis B

  • 09:30-10:30

  • Plenary Session

  • 10:30-10:50

  • Coffee Break

10:50-11:50

Symposium 2-4. Direction to Pursue in Hepatitis C Treatment

  • 10:50-11:05

  • How to Manage Patients with Previous Direct-Acting Antiviral Treatment Failure

  • 11:05-11:20

  • How to Manage Difficult-to-Cure Patients: Decompensated Disease and Transplantation

  • 11:20-11:35

  • Managing Drug-Interaction, Adherence, and Adverse Events in the Era of Pangenotypic Direct-Acting Antiviral

  • 11:35-11:50

  • Multidisciplinary Approach to Predict Fibrosis Progression and Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy

  • 11:50-12:50

  • Luncheon Symposium

12:50-13:20

State-of-the-Art Lecture 2

  • 12:50-13:20

  • The Road to Curing Hepatitis B Virus Infection: Past, Present, and Future

13:20-14:20

Keynote Lecture 2. Cure of Viral Hepatitis. Is This Safe against the Development of Hepatocellular Carcinoma?

  • 13:20-13:40

  • Development of Hepatocellular Carcinoma after HBsAg Seroclearance

  • 13:40-14:00

  • Occult Hepatitis B Infection and Hepatocellular Carcinoma Development

  • 14:00-14:20

  • Molecular Mechanism of Hepatocarcinogenesis after Sustained Virological Response in Patients with Hepatitis C Virus

  • 14:20-14:40

  • Coffee Break

14:40-16:00

APASL-AASLD Joint Session. A New Area of Interest in Chronic Hepatitis B: to Treat or Not to Treat

  • 14:40-15:00

  • Classification and Clinical Characteristics of Gray Zone in Chronic Hepatitis B

  • 15:00-15:20

  • HBeAg-Positive "Gray Zone": Should We Treat and Why?

  • 15:20-15:40

  • HBeAg-Negative "Gray Zone": Should We Treat and Why?

  • 15:40-16:00

  • Do We Need to Expand the Treatment Criteria for "Gray Zone"?

  • 16:00-16:20

  • Coffee Break

16:20-17:40

Symposium 2-7. Debate Session. Strategies to Achieve HBsAg Seroclearance

  • 16:20-16:35

  • Stopping Antivirals

  • 16:35-16:50

  • Continuing Antivirals

  • 16:50-17:05

  • Panel Discussion Interferon or Interferon-Based Therapy

  • 17:05-17:20

  • Newer Antiviral Agents

  • 17:20-17:40

  • Panel Discussion

08:30-09:30

Symposium 2-2. Update of Cirrhosis and Portal Hypertension

  • 08:30-08:45

  • Liver and Spleen Stiffness for the Estimation of Portal Hypertension and Cirrhotic Complications

  • 08:45-09:00

  • Antiviral Treatment and the Improvement of Portal Hypertension and Cirrhosis Complications

  • 09:00-09:15

  • Optimal Assessment and Improving Survival of Acute-on-Chronic Liver Failure

  • 09:15-09:30

  • The Role of Antibiotic Therapy in Acute Decompensation

09:30-10:30

Symposium 2-3. Non-B non-C Viral Hepatitis: Pathogenesis and Treatment

  • 09:30-09:45

  • Immunopathogenesis of Acute Hepatitis A

  • 09:45-10:00

  • Novel Therapies for Hepatitis Delta (HDV)

  • 10:00-10:15

  • Disease Burden and Potential Therapeutic Approach to HEV Infection

  • 10:15-10:30

  • Pathogenesis and Management of Non-Hepatotropic Viruses

  • 10:30-10:50

  • Coffee Break

10:50-11:50

Symposium 2-5. Metabolic Disease and Viral Hepatitis

  • 10:50-11:05

  • Hepatitis Virus Infection and the Risk of Nonalcoholic Fatty Liver Disease

  • 11:05-11:20

  • Adverse Effects of Nonalcoholic Fatty Liver Disease on Viral Hepatitis

  • 11:20-11:35

  • Potential Interactive Mechanisms of HBV Infection with Nonalcoholic Fatty Liver Disease

  • 11:35-11:50

  • Effect of Alcohol Drinking on the Outcome of Viral Hepatitis

  • 11:50-12:50

  • Luncheon Symposium

  • 10:30-10:50

  • Coffee Break

13:20-14:20

Hepatology Associates Course

  • 13:20-13:35

  • Interpretating More Than You Know: Liver Disease-Related Test

  • 13:35-13:50

  • Seems Complicated but Simple Treatment: Antiviral Therapy

  • 13:50-14:05

  • Learning Step by Step from Therapeutic Drugs: Systemic Chemotherapy

  • 14:05-14:20

  • Making Your Dream of Becoming the Best CRC a Reality

  • 14:20-14:40

  • Coffee Break

14:40-16:00

Symposium 2-6. Hepatocellular Carcinoma

  • 14:40-15:00

  • Anti-HBV Therapy to Prevent HBV-Associated Hepatocellular Carcinoma

  • 15:00-15:20

  • Anti-HCV Therapy to Prevent HCV-Associated Hepatocellular Carcinoma

  • 15:20-15:40

  • Non-Viral Management to Prevent Hepatocellular Carcinoma

  • 15:40-16:00

  • (Cost-Effective) Risk-Stratified Surveillance for Hepatitis Virus-Associated Hepatocellular Carcinoma

  • 16:00-16:20

  • Coffee Break

16:20-17:40

Artificial Intelligence (AI) and Machine Learning for Liver Disease Management

  • 16:20-16:40

  • Developing AI Model for Predicting Hepatocellular Carcinoma

  • 16:40-17:00

  • Radiomics and Deep Learning for Chronic Liver Disease

  • 17:00-17:20

  • Harnessing Big 'Omics' Data and AI for Drug Discovery in Liver Disease

  • 17:20-17:40

  • Deep Learning-Based Quantification of NASH Progression/Fibrosis Using Liver Histology

07:30-08:20

Early Morning Workshop 1. Emerging Risk Factors of Hepatocellular Carcinoma in Chronic Hepatitis B

  • 07:30-07:50

  • Impact of Metabolic Factors on the Risk of HBV-Related Hepatocellular Carcinoma

  • 07:50-08:10

  • Have Risk Factors for HBV-Related Hepatocellular Carcinoma Changed Over the Decades?

  • 08:10-08:20

  • Discussion

09:30-10:30

SIG 3. Immunopathogenesis of Viral Hepatitis

  • 09:30-09:45

  • Immunopathogenesis of Viral Hepatitis

  • 09:45-10:00

  • Immunology of Hepatitis B Virus Mouse Models

  • 10:00-10:15

  • Characteristics of B Cells in HBV-Infected Liver

  • 10:15-10:30

  • Chronic Viral Hepatitis and Liver Fibrosis

13:20-14:20

SIG 4. Translational Research for Virus-Induced Hepatocarcinogenesis

  • 13:20-13:35

  • Distinctive Immunological Traits during Virus-Induced Hepatocarcinogenesis

  • 13:35-13:50

  • Activation of TERT Promotor in Virus-induced Hepatocarcinogenesis: Actionable Target?

  • 13:50-14:05

  • Is Virus-Induced Hepatocellular Carcinoma Really More Responsive to Immune-based Therapies Than Non-Viral HCC?

  • 14:05-14:20

  • Novel Blood-Based Biomarkers for Diagnosis of Hepatocellular Carcinoma in Chronic Viral Hepatitis

  • 14:20-14:40

  • Coffee Break

14:40-16:00

Oral Presentation

07:30-08:20

Early Morning Workshop 2. Real-Life Experiences in Hepatitis C Virus Management

  • 07:30-07:50

  • Does Metabolic Derangement Corrected after Cure of Hepatitis C Virus?

  • 07:50-08:10

  • Effects of Direct-Acting Antiviral Treatment on Extrahepatic Manifestations in Hepatitis C Virus Infection

  • 08:10-08:20

  • Discussion